Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 341

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 341
---
 of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment.Three Months Ended March 31,20252024Program expenses(1)IMM-1-104$4,257,936 $3,646,159 IMM-6-4151,623,755 1,027,570 Other programs1,242,109 2,050,612 Non-program expenses(2)1,204,385 1,307,366 Employee-related costs5,378,938 5,729,077 Stock-based compensation expense1,692,267 1,474,758 Depreciation and amortization85,261 90,208 Other segment items(3)(438,519)(1,017,921)Net loss$15,046,132 $14,307,829 (1) Includes direct research and development expenses.(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.(3) Includes interest income and other (income) expense.

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including the audited consolidated financial statements and notes thereto. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. We aim to achieve this goal through Deep Cyclic Inhibition® ("DCI") of clinically-validated core signaling pathways such as the mitogen-activated protein kinase ("MAPK") pathway, impacting cancer cells while sparing healthy cells. Our inclusive approach differentiates us from chronically targeted precision therapies, which are generally limited by toxicity